Dupilumab effectiveness and safety in patients with chronic rhinosinusitis with nasal polyps: Two-year results from the Assessing long-teRm Outcomes in dupiluMAb registry.

What was studied

This study followed adults with chronic rhinosinusitis with nasal polyps. All of them were starting the drug dupilumab in normal care. It was a registry study that tracked people going forward. It was a phase 4 study run in many countries. The plan was to follow people for up to 36 months. This report gives results up to month 24.

What they found

By May 2024, 691 people had started dupilumab. Some had asthma, and some had had past sinus surgery. Blocked nose was scored from 0 to 3. This score fell from 1.8 at the start to 0.5 at month 24. Gains were seen as early as month 3. The loss of smell score fell from 2.2 to 0.9 by month 24. A 22-item nose and sinus test fell from 45.9 to 18.4. In the first 6 months, some people had at least 1 health problem during treatment.

What it means for patients

The authors say dupilumab quickly eased nose symptoms. They say it also made daily life better for people. These gains kept going through 24 months. The authors say the results support that the drug works and is safe long term. They say this is in everyday care, not just in trials.

Why it is not certain yet

There was no group of people who did not take the drug. So it is hard to know how much change came from the drug itself. The abstract gives data on health problems only for the first 6 months. It does not say how many people were still in the study at month 24. The study plans 36 months, but these results stop at 24 months.

Source

Dupilumab effectiveness and safety in patients with chronic rhinosinusitis with nasal polyps: Two-year results from the Assessing long-teRm Outcomes in dupiluMAb registry.

We restate facts from the source record in our own words. The original wording belongs to its publisher.